1118567-46-6

Basic information

• Product Name: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxytetrahydropyran-3,4,5-triol
• Synonyms: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxytetrahydropyran-3,4,5-triol
• CAS NO: 1118567-46-6
• Molecular Weight: 494.969
• Mol File: 1118567-46-6.mol

Chemical Properties

• CAS DataBase Reference: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxytetrahydropyran-3,4,5-triol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxytetrahydropyran-3,4,5-triol(1118567-46-6)
• EPA Substance Registry System: (2S,3R,4S,5S,6R)-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-(hydroxymethyl)-2-methoxytetrahydropyran-3,4,5-triol(1118567-46-6)

Safety Data

• Hazardous Substances Data: 1118567-46-6(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 1118567-45-5 4-bromo-1-chloro-2-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]benzene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 90-80-2 D-Glucono-1,5-lactone 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 864070-18-8 4-(5-bromo-2-chlorobenzyl)phenol 
• 862728-59-4 2-(cyclopropyloxy)ethyl-4-methylbenzenesulfonate 
• 20117-44-6 2-(cyclopropyloxy)ethan-1-ol 
• 18742-02-4 2-bromo-2-(2-ethyl)dioxolane 

Downstream Products

• 1118567-05-7 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1358579-61-9 tert-butyldimethyl-[[(2R,3R,4S,5R,6S)-3,4,5-tri-benzyloxy-6-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-methoxytetrahydropyran-2-yl]methoxy]silicon 
• 1358579-12-0 (1S,2S,3S,4R,5S)-5-[4-chloro-3-[[4-[2-(cyclopropoxy)ethoxy]phenyl]methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol 
• 1358579-72-2 [(1S,2S,3S,4R,5S)-2,3,4-tri-benzyloxy-5-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6,8-dioxabicyclo[3.2.1]octan-1-yl]methanol 
• 1358579-69-7 [(3S,4S,5R,6S)-3,4,5-tri-benzyloxy-6-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-2-(hydroxymethyl)-6-methoxytetrahydropyran-2-yl]methanol 
• 1358579-67-5 (2S,3S,4S,5R,6S)-3,4,5-tri-benzyloxy-6-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-methoxytetrahydropyran-2-formaldehyde 
• 1358579-65-3 [(2R,3R,4S,5R,6S)-3,4,5-tri-benzyloxy-6-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-6-methoxytetrahydropyran-2-yl]methanol 
• 1358579-58-4 (2S,3R,4S,5S,6R)-6-[[tert-butyl(dimethyl)silyloxy]methyl]-2-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-2-methoxytetrahydropyran-3,4,5-triol 

Relevant articles and documents

Glucopyranosyl derivative and application thereof in medicines

The invention relates to a glucopyranosyl derivative used as a sodium-dependent glucose transporter (SGLT) inhibitor, a medicinal composition containing the derivative, and an application of the derivative and the medicinal composition in medicines, and especially relates to the glucopyranosyl derivative represented by formula (I) or a pharmaceutically acceptable salt or all stereoisomers thereof, or the medicinal composition containing the derivative, and a use of the derivative and the medicinal composition in the preparation of medicines for treating diabetes and diabetes related diseases.

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition are also disclosed.

CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR

Crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2 are disclosed. Pharmaceutical compositions, methods for preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition are also disclosed.

PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS

Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.

BENZYLBENZENE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.